Angiogenesis Inhibitors: all 4,430 studies that test it

Page 25 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.

• A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERSWithdrawnNCT04126044Phase 1
• A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma PatientsActive, not recruitingNCT04124497Phase 2
• CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical CancerStatus unknownNCT04121975Phase 2
• R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II StutyStatus unknownNCT04120350Phase 1/2
• Treat and Extend Analysis Trial With Aflibercept in Wet-AMDStatus unknownNCT04113538Phase 3
• Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT04113226Phase 2
• The Sahlgrenska Anti-VEGF StudyActive, not recruitingNCT04101877Phase 2
• Ixazomib + Pomalidomide + Dexamethasone In MMActive, not recruitingNCT04094961Phase 1/2
• Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLCStatus unknownNCT04094909Phase 2
• Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)CompletedNCT04087746Phase 4
• PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBVStatus unknownNCT04084626Phase 3
• Treatment of Polypoidal Choroidal Vasculopathy in PachychoroidCompletedNCT04075188Not applicable
• Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6TerminatedNCT04074785Early Phase 1
• Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT04072679Phase 1
• Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm PatientsCompletedNCT04072198Phase 2
• S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationActive, not recruitingNCT04071457Phase 3
• Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract SurgeryWithdrawnNCT04067856Not applicable
• Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM PatientsCompletedNCT04065789Phase 2
• Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLCStatus unknownNCT04063449Not applicable
• Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract SurgeryStatus unknownNCT04063358Phase 3
• Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein OcclusionStatus unknownNCT04062370Phase 4
• Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedNCT04052880Phase 2
• DNA Vaccination Against NeuroblastomaStatus unknownNCT04049864Early Phase 1
• MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsCompletedNCT04032626Phase 2
• Biomarker Guided Treatment in DLBCLStatus unknownNCT04025593Phase 2
• Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)Active, not recruitingNCT04017455Phase 2
• Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090CompletedNCT04015180Phase 3
• Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMActive, not recruitingNCT04009109Phase 2
• Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCStatus unknownNCT03991403Phase 3
• S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant AscitesStatus unknownNCT03990103Phase 2
• Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaActive, not recruitingNCT03980171Phase 1/2
• One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to BevacizumabCompletedNCT03974425Not applicable
• Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With RanibizumabStatus unknownNCT03973138Phase 1/2
• A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT03973112Phase 2
• Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal AdenocarcinomaStatus unknownNCT03966118Phase 2
• A Study to Desensitize Allergic Reactions to Treatments for Blood DisordersCompletedNCT03959358Phase 2
• A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03952403Phase 3
• TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Phase 3
• Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
• Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract SurgeryStatus unknownNCT03944070Not applicable
• Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV TreatmentCompletedNCT03941587Not applicable
• Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal CarcinomaStatus unknownNCT03932266Phase 2
• Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)Active, not recruitingNCT03921671Phase 2
• Cataract DME - Peri vs. IntraopWithdrawnNCT03920878Phase 2
• Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)Status unknownNCT03912402Phase 2
• Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)Status unknownNCT03909724Phase 2/3
• Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03909334Phase 2
• Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast CancerStatus unknownNCT03907098Phase 2
• A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell CarcinomaTerminatedNCT03905889Phase 1
• Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver GeneStatus unknownNCT03905317Phase 2
• Bevacizumab After Chemoradiotherapy For Locally Advanced Lung AdenocarcinomaCompletedNCT03904563Phase 2
• Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)Active, not recruitingNCT03896074Phase 2
• Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCLStatus unknownNCT03891355Phase 2
• Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent GlioblastomaCompletedNCT03890952Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentCompletedNCT03847428Phase 3
• Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1TerminatedNCT03845049Phase 3
• A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT03844074Phase 3
• Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal CancerWithdrawnNCT03843853Phase 2
• Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaWithdrawnNCT03841565Phase 2
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial CancerWithdrawnNCT03836157Phase 2
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAActive, not recruitingNCT03829371Phase 4
• QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.Active, not recruitingNCT03828227Phase 3
• Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and NeckCompletedNCT03818061Phase 2
• Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPCActive, not recruitingNCT03813394Phase 1/2
• Study to Demonstrate Clinical Benefit of Lenalidomide and DexamethasoneActive, not recruitingNCT03809780Phase 2
• Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian CancerWithdrawnNCT03806049Phase 3
• Effect Aflibercept on Ocular PerfusionCompletedNCT03804099Phase 4
• Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment FailureCompletedNCT03802240Phase 3
• Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell LymphomaCompletedNCT03798314Phase 1
• Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasCompletedNCT03797625Phase 2
• Clinical Study of Endostatin in Improving Radiation Pneumonia and FibrosisCompletedNCT03796364Phase 2
• Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLStatus unknownNCT03795571Phase 1
• A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.Status unknownNCT03794440Phase 2/3
• A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyWithdrawnNCT03785184Phase 2
• Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT)CompletedNCT03780361Phase 4
• Alectinib in Combination With Bevacizumab in ALK Positive NSCLCCompletedNCT03779191Phase 2
• A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive, not recruitingNCT03778957Phase 3
• The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With MegestrolStatus unknownNCT03777930Phase 4
• Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular DegenerationCompletedNCT03777254Phase 1
• Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric CancerWithdrawnNCT03766607Phase 2
• Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.CompletedNCT03766425Early Phase 1
• Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal DystrophyCompletedNCT03763227Phase 2
• Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior TherapyCompletedNCT03762564Phase 2
• Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular EdemaStatus unknownNCT03759860Phase 4
• A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsStatus unknownNCT03757936Phase 1
• Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple MyelomaActive, not recruitingNCT03756896Phase 2
• A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic SyndromesCompletedNCT03746041Phase 1
• RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaCompletedNCT03745430Phase 1/2
• MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03739801Phase 1/2
• Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedNCT03733691Phase 2
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaStatus unknownNCT03730740Phase 2
• Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT03720041Phase 3
• Multi-Center Study of GSK2857916 in Combination With Pomalidomide and DexActive, not recruitingNCT03715478Phase 1/2
• R2 in the Treatment of Follicular LymphomaStatus unknownNCT03715309Phase 2
• The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver MetastasesStatus unknownNCT03711240Phase 2
• Eylea and Lucentis for Macular Edema in Branch Retinal Vein OcclusionCompletedNCT03709745Phase 4
• Rh-Endostatin (Endostar®) Continuous Intravenous InfusionStatus unknownNCT03706703Phase 2

← Angiogenesis Inhibitors overview